The anticoagulated trauma patient

The anticoagulated trauma patient is the patient whose bleeding is amplified by the medication that was prescribed to prevent the thrombosis — the warfarin, the direct oral anticoagulants (the dabigatran, apixaban, rivaroxaban), and the antiplatelet agents (the aspirin, the clopidogrel). The emergency physician must know which agent the patient is on, how to reverse each one rapidly, and how to integrate the reversal with the trauma resuscitation. The key principle is the early reversal in parallel with the resuscitation — the haematoma expands and the bleeding continues while the confirmatory testing is awaited.[1][1]

The reversal agents — management and dosing

Warfarin. The reversal is the prothrombin complex concentrate (the PCC) at 25 to 50 units per kilogram intravenously (the dose by the INR and the weight), which restores the factors rapidly (within minutes), together with the intravenous vitamin K (10 milligrams), which restores the endogenous production over 6 to 12 hours (so the PCC buys the time for the vitamin K to work). The fresh frozen plasma is the alternative if the PCC is unavailable, but it is slower, requires the larger volume, and carries the infection and the TRALI risk.[1][1]

Dabigatran (the direct thrombin inhibitor). The specific antidote is the idarucizumab (5 grams intravenously, in two 2.5-gram doses), which binds the dabigatran directly and reverses the anticoagulant effect within minutes. The RE-VERSE AD study and its subgroups, including the urgent-surgery subgroup, confirmed the efficacy and the safety.[2][1]

Apixaban and rivaroxaban (the factor Xa inhibitors). The specific antidote is the andexanet alfa (the low or the high dose by the drug, the dose and the timing), which binds and sequesters the factor Xa inhibitor. The andexanet is effective but expensive, associated with the thrombotic events, and not universally available. The PCC (or the activated PCC, the factor VIII inhibitor bypassing activity) is the widely available alternative that reverses the bleeding by replenishing the factors, though without the direct measurement of the anti-Xa effect.[1][1]

Antiplatelet agents (the aspirin, the clopidogrel). The reversal is the platelet transfusion in the actively bleeding patient (the intracranial haemorrhage, the life-threatening bleeding), though the evidence for the benefit is limited and the transfusion is not given routinely for the non-life-threatening bleeding. The desmopressin (the DDAVP) is sometimes used for the aspirin effect on the platelet function.[1]

References9Show ledgerHide ledger

1. [1]Rossaint R, Bouillon B, Cerny V, et al. The European guideline on management of major bleeding and coagulopathy following trauma: sixth edition Crit Care, 2023.PMID 36859355
2. [2]Levy JH, van Ryn J, Sellke FW, et al. Dabigatran Reversal With Idarucizumab in Patients Requiring Urgent Surgery: A Subanalysis of the RE-VERSE AD Study Ann Surg, 2021.PMID 31599808
3. [3]Shakur H, Roberts I, Bautista R, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial Lancet, 2010.PMID 20554319
4. [4]CRASH-3 trial collaborators (Dewan Y, et al.). Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial Lancet, 2019.PMID 31623894
5. [5]Pollack CV Jr, Reilly PA, Eikelboom J, et al. Idarucizumab for Dabigatran Reversal N Engl J Med, 2015.PMID 26095746
6. [6]Connolly SJ, Crowther M, Eikelboom JW, et al. Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors N Engl J Med, 2019.PMID 30730782
7. [7]Holcomb JB, Tilley BC, Baraniuk S, et al. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial JAMA, 2015.PMID 25647203
8. [8]Christensen H, Cordonnier C, Kõrv J, et al. European Stroke Organisation Guideline on Reversal of Oral Anticoagulants in Acute Intracerebral Haemorrhage Eur Stroke J, 2019.PMID 31903428
9. [9]El Naamani K, Abbas R, Ghanem M, et al. Resuming Anticoagulants in Patients With Intracranial Hemorrhage: A Meta-Analysis and Literature Review Neurosurgery, 2024.PMID 37459580